Status:

UNKNOWN

Stereotactic Radioablation for the Treatment of Refractory Atrial Fibrillation

Lead Sponsor:

National and Kapodistrian University of Athens

Collaborating Sponsors:

Medtronic

Conditions:

Atrial Fibrillation

Arrythmia

Eligibility:

All Genders

65-89 years

Phase:

NA

Brief Summary

The study aims to investigate the short-term (3 months) and intermediate-term (12 months) safety and preliminary efficacy of stereotactic radiotherapy for pulmonary vein isolation to treat refractory ...

Detailed Description

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. Current guidelines recommend catheter ablation of AF in symptomatic patients refractory to antiarrhythmic therapy. Pulmonary v...

Eligibility Criteria

Inclusion

  • Age 65-89
  • Paroxysmal or persistent symptomatic AF refractory to antiarrhythmic drugs.
  • Failure from the previous catheter ablation of AF, or contraindicate /unwilling to undergo catheter ablation.
  • Dual chamber pacemaker implanted
  • Understands the nature of the study, treatment procedure and provides written informed consent
  • Willing to comply with specified pre-, post- and follow-up testing, evaluations and requirements

Exclusion

  • Permanent AF
  • Unstable angina
  • Presence of any disease that is likely to shorten life expectancy to \< 1 year
  • Any cardiac surgery within three months prior to enrolment
  • Awaiting cardiac transplantation or other cardiac surgery within the next year
  • Myocardial infarction (MI) within 60 days prior to enrolment
  • Contraindications to oral anticoagulation
  • Active systemic infection or sepsis
  • History of a documented thromboembolic event such as stroke or transient ischemic neurological attack (TIA) in the three months prior to enrollment.
  • Any other clinical condition that might jeopardize patient safety during participation in this trial or prevent the subject from adhering to the trialprotocol
  • Esophageal ulcer.

Key Trial Info

Start Date :

May 10 2021

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

August 30 2022

Estimated Enrollment :

15 Patients enrolled

Trial Details

Trial ID

NCT04833712

Start Date

May 10 2021

End Date

August 30 2022

Last Update

April 6 2021

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Attikon University Hospital

Chaïdári, Greece

2

Mediterraneo Hospital

Glyfada, Greece